Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?

Immunovant, Inc. (IMVT) closed the last trading session at $17.49, gaining 14.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of$ 41.57 indicates a 137.7% upside potential.The average comprises 14 short-term price targets ranging from a low of $17.00 to a high of$ 61.00, with a standard deviation of $15.37. While the lowest estimate indicates a decline of 2.8% from the current pric ...